(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 January 2007 (25.01.2007)

PCT

(10) International Publication Number
WO 2007/011349 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 31/542* (2006.01)
A61K 9/16 (2006.01) *A61K 31/5415* (2006.01)

(21) International Application Number:
PCT/US2005/025326

(22) International Filing Date: 15 July 2005 (15.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant *(for all designated States except BB, US)*: **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petah Tiqva (IL).

(71) Applicant *(for BB only)*: **TEVA PHARMACEUTICAL USA, INC.** [US/US]; 1090 Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ZALIT, Ilan** [IL/IL]; Mivtza Dany St. 3, Rosh-Ha-Ayin (IL). **HRAKOVSKY, Julia** [IL/IL]; Mivza Uvda Str. 6/4, 48057 Rosh-Ha-Ayin (IL). **TENENGAUZER, Ruth** [IL/IL]; Ben Gamla 9/4, 45322 Hod Hasharon (IL). **SHALOM-KLEIN, Sagit** [IL/IL]; Nahala 8, 52335 Ramat Gan (IL).

(74) Agents: **BRAINARD, Charles** et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004-1050 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** NOVEL GRANULATION PROCESS AND GRANULATE PRODUCED THEREFROM

(57) **Abstract:** One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and a solvent, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture; (b) drying the combined mixture of step (a); and (c) comminuting the product of step (b) to obtain the granulate.

WO 2007/011349 A1

Attorney Docket No. 01662/86276

NOVEL GRANULATION PROCESS AND GRANULATE PRODUCED THEREFROM

FIELD OF THE INVENTION

The present invention relates to granulates containing an active pharmaceutical ingredient having poor water solubility intimately associated with a pharmaceutically acceptable sugar, useful for pharmaceutical formulations, as exemplified by formulations of bicalutamide or fenofibrate suitable for tablets manufacture.

BACKGROUND OF THE INVENTION

The solubility of an active pharmaceutical ingredient (API) influences the bioavailability of the drug and the dissolution of the drug can often set an upper limit on the rate of absorption of the drug. Many active pharmaceuticals have poor solubility in water and typically, thus lower bioavailability. Reduction in the particles size and concomitant increase in surface area of an active pharmaceutical ingredient has been used, with some success, to improve the dissolution of active pharmaceutical ingredients. However, this approach is limited by the particle size that can be achieved and by poor bulk flow and handling characteristics of finely powdered active pharmaceutical ingredients.

Strong milling of conventional granulates can increase the surface area of an active ingredient incorporated therein. This can result in a very powdery, difficult to handle fine powder. Re-granulation of this powder to improve handling can cause a reduction in surface area. Use of a higher content of a stiff binder can enable an increase in dissolution, presumably by increased surface area, but the extent of improvement is limited. In an anonymous article entitled "Formulations Comprising Lipid-Regulating Agents" published July 11, 2002 and appeared in the August 2002 issue of IP.com Journal Volume 2 number 8, publication identifier 'IPCOM000008767D', there is mention made of "stronger" granules of fenofibrate made using "syrup solution of lactose" as a binder solution that with milling can increase the surface area and rate of dissolution, no significant detail is available that would enable one to achieve the results required and certainly no indication of the utility for any other API. The contents of this article are hereby incorporated in their entirety.

Clearly there is a need for improved methods for obtaining granulates of pharmaceutical compositions in which the active pharmaceutical ingredient exhibits the largest possible surface area to promote dissolution. The present inventors have surprisingly

found that combining a solution of a sugar, e.g. lactose, with the ingredients of a pharmaceutical granulate formulation as herein described results in a granulate that can be comminuted to give a particulate that can be used to make an oral solid dosage form exhibiting surprisingly increased dissolution of the active pharmaceutical ingredient.

SUMMARY OF THE INVENTION

One of the aspects of the invention concerns a granulate for a pharmaceutical composition, useful for making, among other things, oral solid dosage forms such as capsules and tablets, wherein the granulate comprises an active pharmaceutical ingredient (i.e. "API), which has poor water solubility, intimately associated with at least one pharmaceutically acceptable sugar, e.g., a pyranosyl pyranose such as lactose, and, optionally, at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar. The active pharmaceutical ingredient having poor water solubility includes fenofibrate, bicalutamide, atorvastatin, fluvastatin, simvastatin, candesartan, ezetimibe, oxcarbazepine, meloxicam, celecoxib, rofecoxib, valdecoxib, raloxifene, aripiprazole or glyburide. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is preferably included in the granulate.

The present invention also relates to a process for making a granulate of a pharmaceutical composition, useful for making, among other things, oral solid dosage forms, comprising the steps of (a) combining an active pharmaceutical ingredient (i.e. "API") having poor water solubility with a solution of at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture, wherein the solution comprises the at least one pharmaceutically acceptable sugar and at least one solvent; (b) drying the combined mixture of step (a); and (c) comminuting the product of step (b) to obtain the granulate. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is preferably included in the combining step (a). The at least one solvent in the solution of the at least one pharmaceutically acceptable sugar is preferably water.

Suitable pharmaceutically acceptable excipients include a polymer or copolymer of vinyl pyrrolidone and a wetting agent, for example sodium lauryl sulfate. Other pharmaceutically acceptable excipients, especially microcrystalline cellulose, can be and preferably are combined in the process. The product of comminution is termed a granulate and can be used directly as a pharmaceutical formulation, or it can be and preferably is

blended with one or more additional pharmaceutically acceptable excipients prior to use, which can be one or more of pharmaceutically acceptable sugars and pharmaceutically acceptable excipients other than the one or more of pharmaceutically acceptable sugars. The advantages of the current invention are only realized when the granulate is the product of comminution as defined above

In another aspect, the present invention relates to a process for making a granulate of a pharmaceutical composition, useful for making, among other things, oral solid dosage forms whereby bicalutamide, a known non-steroidal anti-androgen agent, is combined with a solution of at least one pharmaceutically acceptable sugar, for example lactose, and at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar. Suitable pharmaceutically acceptable excipients include a polymer or copolymer of vinyl pyrrolidone and a wetting agent, for example sodium lauryl sulfate. Other pharmaceutically acceptable excipients, especially microcrystalline cellulose, can be, and preferably are, combined in the process. The combined product is dried and comminuted to form a particulate. The particulate is a granulate of the present invention and can be used directly as a pharmaceutical formulation, or it can be and preferably is blended with one or more additional pharmaceutically acceptable excipients prior to use, which can be one or more of pharmaceutically acceptable dissaccahrides and pharmaceutically acceptable excipients other than sugars.

In yet another aspect, the present invention relates to a process for making a granulate of a pharmaceutical composition, useful for making, among other things, oral solid dosage forms, whereby an active pharmaceutical ingredient, especially bicalutamide, having poor water solubility is combined with microcrystalline cellulose, at least one non-crosslinked polymer of vinyl pyrrolidone, at least one disintegrant and wetting agent and an aqueous solution (for example, ca. 1:1, wt.:wt.) of lactose. The combined product is then dried and comminuted, for example by high-energy milling, to form a particulate that is a granulate of the present invention and can be used directly or it can be, and preferably is, blended with one or more additional pharmaceutically acceptable excipients prior to use, which can be one or more of pharmaceutically acceptable disaccharides and pharmaceutically acceptable excipients other than sugars.

In yet another aspect, the present invention relates to the granulate prepared by any of the processes described above.

In still another aspect, the present invention relates to a granulate prepared by combining bicalutamide, microcrystalline cellulose, croscarmellose sodium, povidone

(polyvinylpyrrolidone, "PVP"), sodium lauryl sulfate and an aqueous solution of lactose monohydrate to form a combined product, drying the combined product, blending the dried combined product with colloidal silicon dioxide, and comminuting the resulting blend to obtain the granulate.

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 depicts the dissolution profile of fenofibrate tablets prepared from Formulation 1 described below, and the dissolution profile of commercial fenofibrate tablets, Tricor 160 mg.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides granulates of a pharmaceutical composition having an active pharmaceutical ingredient, i.e. a drug, having poor water solubility and a method for making the granulate. The granulates are useful for making oral solid dosage forms, for example capsules and compressed tablets in a variety of shapes. The advantages of the present inventive composition and method are notable with active pharmaceutical ingredients that have poor solubility in water. An API or drug is considered poorly water soluble if it has a solubility of less than about 20 mg per ml of water at about 25°C.

In this application, the term "active pharmaceutical ingredient, which has poor water solubility" or "active pharmaceutical ingredient having poor water solubility" means an API or drug having a solubility in water of less than about 20 mg per ml at about 25°C. Examples of the "active pharmaceutical ingredient, which has poor water solubility" or "active pharmaceutical ingredient having poor water solubility" include fenofibrate, bicalutamide, atorvastatin, fluvastatin, simvastatin, candesartan, ezetimibe, oxcarbazepine, meloxicam, celecoxib, rofecoxib, valdecoxib, raloxifene, aripiprazole or glyburide. Bicalutamide is a poorly water soluble active pharmaceutical agent particularly well suited for use in the present invention.

In the granulate for pharmaceutical composition of the invention, the active pharmaceutical ingredient (API) having poor water solubility and the at least one pharmaceutically acceptable sugar are intimately associated or in intimate association. The term "intimately associated" or "intimate association" refers to a state produced by a process comprising mixing the API and a solution of the at least one pharmaceutically acceptable sugar to form a mixture and drying the mixture. The API and the at least one pharmaceutically acceptable sugar in the dried mixture are intimately associated or in

intimate association. The dried mixture in intimate association can be comminuted later to obtain granulates of an appropriate size. The state of being "intimately associated" or in "intimate association" is different from an ordinary state resulting from mixing powders of the API and powders of the at least one pharmaceutically acceptable sugar, optionally followed by compaction of the powder mixture. The intimate-association state differs from the ordinary state generated by mixing the API powders and sugar powders at least in that the at least one pharmaceutically acceptable sugar is more tightly adhered to the API in the intimate-association state than the ordinary state. In the intimate-association state of the pharmaceutical composition of the invention, the at least one pharmaceutically acceptable sugar forms a fairly or substantially continuous solid phase around a powder or granule of the API.

It is understood that pharmaceutical formulations comprising sugars not intimately associated with drugs were known in the pharmaceutical arts. In contrast, in the pharmaceutical composition of the invention, the API having poor water solubility and the at least one pharmaceutically acceptable sugar are in intimate association, with the API and the at least one pharmaceutically acceptable sugar combined in a matrix having a fairly or substantially continuous phase achieved by drying a mixture of the API and a solution of the at least one pharmaceutically acceptable sugar. The matrix of the intimate association of the API and the at least one pharmaceutically acceptable sugar achieves a consistency and stable adherence between the API and sugar(s) not achievable with the prior art process of mixing powders of the corresponding API with powders of the least one pharmaceutically acceptable sugar. As a result of the intimate association (and the milling of the dried granules), the pharmaceutical composition of the invention has superior dissolution properties than the prior art powder mix of the corresponding API and the at least one pharmaceutically acceptable sugar.

The pharmaceutical compositions of the invention are distinguished from the prior art products of classic lyophilization or freeze-drying where in contrast to the compositions of the present invention, the resultant product of that prior art technique generally results in a "cake" of a fluffy fragile matrix that can reportedly achieve improved dissolution by the "airy" and or porous nature of the matrix resulting from the lyophilization technique. It is however contemplated that, in the process for making the granulate of a pharmaceutical composition according to the present invention, the step of drying the combined mixture may include procedures where this drying is achieved at least partially by sublimation.

A poorly water soluble active pharmaceutical agent incorporated, by being intimately associated with at least one pharmaceutically acceptable sugar, into the granulate of the pharmaceutical composition of the present invention dissolves faster and to a greater extent in aqueous media than does the same poorly water soluble active pharmaceutical agent incorporated into a granulate or tablet made by conventional methods and/or by direct compression methods. The improved dissolution of the active pharmaceutical ingredient having poor water solubility in the granulate of the present invention, compared with the same active pharmaceutical ingredient incorporated into a granulate made by conventional methods, can be determined by tests conducted under conditions at least as stringent as using 1000 ml of a 1% aqueous solution of sodium lauryl sulfate at 37° C with the USP paddle method rotating at 50 rpm and sampling time of 15, 30, 45 or 60 min, wherein if the active pharmaceutical ingredient is bicalutamide the amount of bicalutamide released is determined with a UV detector at 272 nm. For example, the granulate prepared by the method of the present invention can be fabricated into a compressed tablet and the dissolution of the active pharmaceutical ingredient determined by a suitable technique, for example dissolution test <711> of the United States Pharmacopoeia, and compared to the dissolution measured for a tablet compressed using conventionally produced granulate. When the active pharmaceutical ingredient is bicalutamide, a pharmaceutical dosage form comprising the granulate of the invention can have a dissolution property in which at least 50% of the bicalutamide dissolves in about 15 minutes, preferably at least about 65% of the bicalutamide dissolves in about 30 minutes, and more preferably at least 75% of the bicalutamide dissolves in about 45 minutes when tested under conditions at least as stringent as 1000 ml of a 1% aqueous solution of sodium lauryl sulfate at 37° C using a USP paddle method rotating at 50 rpm when measured by a UV detector at 272 nm. For instance, when the active pharmaceutical ingredient is bicalutamide, the pharmaceutical dosage form of the invention can release about 80% of the bicalutamide in about 15 minutes or about 95% of the bicalutamide in about 30 minutes, when tested under conditions at least as stringent as 1000 ml of a 1% aqueous solution of sodium lauryl sulfate at 37° C using a USP paddle method rotating at 50 rpm when measured by a UV detector at 272 nm.

In the instant patent application, the term "at least one pharmaceutically acceptable sugar" refers to a pharmaceutically acceptable monosaccharide, disaccharide or mixtures thereof, with the "at least one pharmaceutically acceptable sugar" comprises preferably at least a pharmaceutically acceptable disaccharide. Examples of the "at least one pharmaceutically acceptable sugar" include mannitol, sorbitol, glucose, fructose, galactose

and, preferably, a disaccharide such as sucrose and, more preferably, a pyranosyl pyranose (e.g., maltose, isomaltose, cellobiose, melibiose, gentiobiose and, most preferably, lactose). The "at least one pharmaceutically acceptable sugar" to be combined with the API is in the form of a solution, preferably an aqueous solution or water/organic solution, in a sugar-to-solvent ratio generally between about 0.05:1 to about 1:0.05, preferably about 0.1:1 to about 1:0.1, more preferably about 0.5:1 to about 1:0.5 and most preferably about 1:1 (wt/wt; based on the total weight of the at least one pharmaceutically acceptable sugar : the weight of the solvent in the sugar solution). Depending on the API and the strength of the pharmaceutical dosage form comprising the granulate of the present invention, the weight ratio of the sugar (originated from the granulation solution) and the API having poor water solubility in the granulate can be from about 0.1:1 to about 1000:1, and preferably from about 0.1:1 to about 100:1 or from about 0.1:1 to about 10:1, e.g. about 0.5:1, about 1:1, about 2:1, about 3:1, about 5:1, about 10:1 or about 50:1. For relatively high dose products (e.g. pharmaceutical granules containing bicalutamide), the weight ratio of the sugar and the API having poor water solubility in the granule is preferably about 0.5:1 to about 5:1, e.g. about 0.5:1, about 1:1, about 2:1 or about 3:1, and more preferably about 0.7:1. In one of the embodiments, the present invention provides tablets comprising the granulate of the present invention, wherein the active pharmaceutical ingredient having poor water solubility in the granulate is bicalutamide, wherein the weight ratio of the sugar and bicalutamide can be about 0.7:1.

Many active pharmaceutical ingredients can be administered to a subject, particularly a human, in need of treatment with that active pharmaceutical ingredient in the form of an oral solid dosage form. Compressed tablets, in a variety of shapes, and filled capsules are examples of oral solid dosage forms. Oral solid dosage forms are rarely fabricated from neat active pharmaceutical ingredient. Rather, they are often fabricated of a granulate made by combining an active pharmaceutical ingredient with one or more pharmaceutically acceptable excipients. It is well known that pharmaceutically acceptable excipients can be broadly classified according to their intended function in the granulate or oral solid dosage form. One skilled in the art of pharmaceutical formulation knows that a given excipient may perform more than one function and the function of an excipient can depend on the kind and amount of other excipients used, as well as the particular active pharmaceutical ingredient used.

Classes of pharmaceutically acceptable excipients other than the at least one pharmaceutically acceptable sugar include diluents, binders, lubricants, glidants, disintegrants, wetting agents and coloring and flavoring agents. Common diluents are microcrystalline cellulose (e.g. Avicel®), lactose and starch among many others well known

in the art. Binders also may be included in tablet formulations to help hold the tablet together after compression. Some typical binders are carboxymethylcellulose sodium, ethylcellulose, gelatin, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), povidone (e.g. Kollidon®, Plasdone®), sodium alginate and starch among many others well known in the art. A tablet may further include a disintegrant to accelerate disintegration of the tablet in the patient's stomach. Disintegrants may typically include croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), microcrystalline cellulose, pregelatinized starch, sodium starch glycolate (e.g. Explotab®) among many others well known in the art. A pharmaceutical composition for making compressed tablets may further include glidants, lubricants, flavorings, colorants and other commonly used pharmaceutically acceptable excipients.

Within the scope of the present invention is a novel process of preparing a pharmaceutical granulate that includes the steps of combining an active pharmaceutical ingredient having poor water solubility with a solution, preferably aqueous, of at least one pharmaceutically acceptable sugar and optionally at least one or, preferably more than one, pharmaceutically acceptable excipients other than the at least one pharmaceutically acceptable sugar; drying the product of the combining step; and comminuting the dried product. Suitable pharmaceutically acceptable excipients include a polymer or copolymer of vinyl pyrrolidone and a wetting agent, for example sodium lauryl sulfate. The combining can be by any mixing or dispersing means as is known in the art. For example, weighed ingredients, including the aqueous solution of the at least one sugar, can be combined using a twin-shell mixer of the Patterson-Kelly type, a planetary mixer of the Glen type, or a high shear/high intensity or high speed mixer of the Henschel, Lodige/Littleford, or Baker-Perkins types, to mention just a few. Use of a high shear/high intensity mixer is the preferred means of combining.

In a preferred embodiment of the process of the present invention, at least one pharmaceutically acceptable excipient that is a polymer of vinyl pyrrolidone is included in the combining step and incorporated into the granulate. Suitable polymers of vinyl pyrrolidone include the povidones and crospovidones, available from, for example, the BASF Corporation of Mt. Olive NJ or International Specialty Products of Wayne NJ, USA. Povidone is example of preferred polymers of vinyl pyrrolidone. Preferably, microcrystalline cellulose (e.g., Avicel®, available from FMC Corporation)
is included in the combining step and is incorporated in the granulate.

Following the combining step, the product of the combining step can be dried, for example in a tray drier or fluidized bed drier, optionally sieved, then comminuted to obtain the granulate. The comminuting can be by any means known in the art, for example milling. A Fitzpatrick mill with 0.5 mm screen is suitable for use in the comminuting step. Those who routinely use this type of equipment will know to optimize the time and intensity of comminuting such that additional comminuting does not result in a significant further increase in the rate or extent of dissolution of the API incorporated in the granulate. The rate and extent of dissolution are preferably measured on tablets compressed from granulate and using methods well known in the art and published, for example, in the United States Pharmacopeia.

In a preferred embodiment, collodial silicon dioxide is blended with the dried combined product prior to comminution. The blending can be by any means known in the art, for example with a planetary mixer or high speed mixer.

The granulate obtained can be used directly, or it can be blended with one or more additional pharmaceutically acceptable excipients prior to use. Preferably, granulate is blended with lubricant prior to use, for example prior to being compressed into tablets.

One skilled in the art of pharmaceutical formulation will know to optimize the kinds and amounts of the active pharmaceutical ingredient (API) having poor water solubility and pharmaceutically acceptable excipients depending on the dosage form to be made and the combining and tableting or capsule filling equipment available. In a preferred combining step, the following are combined in a high shear mixer:

from about 0.3 to about 75 wt.-% of the API having poor water solubility,
from about 5 to about 45 wt.-% of diluent(s),
from about 5 to about 15 wt.-% of disintegrant(s),
from about 0.5 to about 8 wt.-% binder(s),
from about 1 to about 10 wt.-% of wetting agent(s), and
from about 1 to about 50 wt-% of the solution (*ca.* 1:1, sugar weight:solvent weight) of the at least one pharmaceutically acceptable sugar.

In the above preferred combining step, about 10 to about 60 wt.-% of API having poor water solubility is sometimes used. The at least one pharmaceutically acceptable sugar used in the preferred combining step above is preferably lactose. An aqueous solution of lactose is particularly preferred as the solution of sugar used in the above preferred combining step. A person skilled in the art can optimize the amount of the aqueous lactose solution used to

obtain a mixture with the desired consistency and comminuting characteristics. The product from combining the above ingredients is dried, blended with a glidant (about 0.5 to 1.5 wt.-% based on the weight of the product from combination), and the resultant mixture comminuted using a suitable mill exemplified by a Fitzpatrick impact mill. The comminuted mixture is processed directly (e.g. pressed into tablet cores), or it can be and preferably is blended with lubricant before processing.

The present invention is illustrated with the following non-limiting examples (e.g. see Table 1). Example 1 and 2 are for comparison purposes. Examples 3 and 4 are working examples.

Example 1:

Experimental batches, numbers K-31049 and K-31050, were manufactured using a direct compression method. The dry ingredients were dry mixed in a blender and compressed into tablets. The dissolution rates of the resultant tablets were too low, i.e. only about 50% of the active pharmaceutical ingredients dissolved after 45 min, when tested in 1000 mL of 0.05 M aqueous SLS solution, padddle at 75 rpm, at 37°C .

Example 2:

Experimental batches, numbers R-00419 and K-31112, were manufactured by wet granulation. The batches were manufactured using a high shear mixer and fluidized bed drier. The extragranular excipients were added to the milled granulate and mixed in a blender. Tablet cores were compressed. Batch R-00419 was manufactured using purified water as a granulation liquid. The resultant tablet's dissolution rate was too low in that only about 58% of the active pharmaceutical ingredient dissolved after 45 min. Batch K-31112 was manufactured using Alcohol 95% as a granulation liquid. The resultant tablet's dissolution rate was also too low in that only about 55% of the active pharmaceutical ingredient dissolved after 45 min on average when tested in 1000 mL of 0.05 M aqueous SLS solution, padddle at 75 rpm, at 37°C.

Example 3 (working example):

Experimental batch K-31557 was manufactured by using a solution of lactose monohydrate in purified water as a granulation solution. The formulation ingredients (bicalutamide, microcrystalline cellulose, povidone, croscarmellose sodium and sodium lauryl sulfate) were combined in a high speed mixer with a solution (1:1, lactose

monohydrate wt:water wt) of lactose monohydrate in purified water. The product from the combining step was dried, blended with colloidal silicon dioxide, and milled in a Fitzpatrick impact mill. The granulate so obtained was blended with microcrystalline cellulose and magnesium stearate and compressed into tablet cores in the usual way and the tablet cores were coated.

Table 1

Batch No. Ingredient	K-31049 Direct compression	K-31050 Direct compression	R-00419 Wet granulation	K-31112 Wet granulation	K-31557 Wet granulation
Bicalutamide	50.0	50.0	50.0	50.0	50.0
Avicel PH 102 (Microcrystalline Cellulose NF)	20.0	20.0	-----	30.0	21.0
Aerosil 200 (Colloidal Silicon Dioxide NF)	3.0	3.0	-----	-----	2.0
Lactose Monohydrate NF 200 Mesh	30.8	30.8	59.8	24.0	35.0
PVP K-30 Povidone USP	3.0	3.0	4.0	2.0	1.5
Ac-Di-Sol (Croscarmellose Sodium NF)	-----	-----	-----	-----	12.5
Sodium Starch Glycolate NF	20.0	20.0	13.0	20.0	-----
Sodium Lauryl Sulfate NF	-----	-----	-----	2.0	4.0
Magnesium Stearate NF	1.2	1.2	1.2	2.0	2.0

The dissolution results are shown in Table 2. the dissolution rates were determined in 1000mL of 0.05 M aqueous SLS solution, padddle at 75 rpm, at 37°C

Table 2

	15 min	30 min	45 min
K-31049	29%	40%	48%
K-31050	31%	45%	53%
R-00419	39%	51%	58%
K-31112	41%	50%	55%

K-31557 (working example)	79%	95%	97%

The dissolution results presented in Table 2 are averages of several tablets, so the dissolution rates of individual tablets might lie above or below the average value.

Example 4 (working example):

Formulation 1

A fenofibrate composition, Formulation 1, was made by the wet granulation process of the present invention. The ingredients in Table 3 were wet granulated and then compressed into tablets each weighing 750 mg.

The process of preparing Formulation1 is an example of applying the basic concept of the invention using a solution of lactose (lactose : water, 1:1, v:v) as a binder in the granulation process, followed by drying the mixture and milling the resulting granules. All other non-API components in the granulation mixture may have an effect on the final results but are not critical for applying the concept of the invention and therefore can be replaced (by different components of the same type) or partially omitted. The weight ratios of the granulation components versus the API can be higher or lower than that in Formulation 1. More preferably, the weight ratios are higher than that in Formulation 1 in order to at least maintain or even increase the dissolution rate compare to the dissolution of Formulation 1.

The amount and concentration of the lactose solution used are important. The making of Formulation 1 used a solution of lactose (lactose : water, 212 mg : 212 mg) equal to 424 mg which is 40% of the total granulation mixture (solids and water) by weight. In general, the solution of the at least one pharmaceutically acceptable sugar can be between about 15 to about 60%, by weight, of the total granulation mixture, and more preferably between about 35 to about 50% of the total granulation mixture. An increase in the amount of lactose (added as a solution) used can further improve the final results of the invention. For example, increasing the total amount of the granulation solution from 424 mg to 500 mg (lactose : water, 250 mg : 250 mg) while maintaining the amounts of the other ingredients constant may improve the dissolution. On the other hand, reducing the total amount of the granulation solution from 424 mg to 250 mg (lactose : water, 125 mg : 125 mg) while maintaining the amounts of the other ingredients constant may reduce the dissolution rate. In Example 4, the granules were intensively milled with Fitzmill™ Communitor equipped with a 0.5 mm screen resulting in powder with particle size distribution shown in Table 4, wherein the particle size was determined with sonic filter methodology using ATM Sonic filter or GilsonAutosiever GA equipped with sieves of 60, 80,100,140,170, and Pan.

Table 3

Ingredient	Weight (mg/tablet)	Approx. Weight Percent
Part I:		
Fenofibrate	160	21.3
Polyvinylpyrrolidone (PVP K-30)	60	8.0
Sodium Starch Glycolate	48	6.4
Croscarmellose Sodium (Ac-di-sol™)	48	6.4
Crospovidone	48	6.4
Microcrystaline Cellulose (Avicel)	139.5	18.6
Part II:		
Sodium Lauryl Sulfate (SLS)	15	2.0
Lactose	212	28.3
Part III:		
Aerosil	7.5	1.0
Part IV:		
Pruv (Sodium Stearyl Fumarate)	12	1.6

The granulates were prepared with a method comprising the following steps:

1. Part I ingredients were thoroughly blended.
2. Lactose of Part II was dissolved in 212 mg of water heated to about 70°C.
3. SLS of Part II was dissolved in about 10mg of water .
4. The blend of step 1 was granulated by adding the lactose and SLS solutions of steps 2 and 3 to form granules.
5. The granules of step 4 were dried in a Fluidized Bed Drier (FBD) (inlet air 55°C, outlet air Not More Than 40°C) .
6. Aerosil of Part III was blended with the dried granules of step 5 and then milled with Fitzmill™ fitted with a 0.5 mm aperture screen.
7. The Part IV ingredients were then blended with the milled granules of step 6 for about 2 minutes to form a final blend.
8. The final blend was compressed into tablets.

Table 4

Particle Size Distribution					
	Retained on (%)				
Sieve size (mesh)	Lot 1 k-29740	Lot 2 k-29738	Lot 3 Lot no F15001	Lot 4 Lot no F15002	Lot 5 Lot no F15003
60	12	9.7	9.9	10.3	10.7
80	15	13.8	11.3	13.3	13.3
100	7.0	6.9	3.4	6.8	6.7
140	14.5	17.9	13.7	11.8	11.1
170	7.1	6.8	3.5	5.2	5.1
PAN	43.3	43.9	57.1	52.7	53.3
Total	98.8	99.0	98.9	100.1	100.2

Table 4 shows that at least about 72% of the milled granules passed through the 80 mesh screen and at least about 66% passed through the 100 mesh screen.

The dissolution profile of the tablets of Lot 1 (K-29740) of Formulation 1 was tested in 1000 mL of 0.05 M aqueous SLS solution, paddle (Apparatus II) at 75 rpm and 37°C. For comparison, the dissolution profile of commercial fenofibrate tablets, Tricor 160 mg, was also tested in the same way. The dissolution profiles obtained are presented in Table 5 and shown graphically in Fig. 1.

Table 5

(Dissolution Profile)

Time (min)	K-29740	Tricor 160 mg
0	0.0	0.0
10	68.0	57.0
20	95.0	94.0
30	99.0	99.0
40	100.0	100.0

The pharmaceutical granulates of the present invention comprising the active pharmaceutical ingredient, e.g. fenofibrate, of poor aqueous solubility intimately associated with the at least one pharmaceutically acceptable sugar can have particle size distribution in that at least about 70% passes through a 80 mesh screen, at least about 60% passes through a

100 mesh screen and at least about 50% passes through a 140 mesh screen.

The solid pharmaceutical formulations, e.g., tablets, of the present invention can display dissolution properties such that after about 10 minutes at least about 50%, preferably at least about 60%, is dissolved; after about 20 minutes at least about 70%, more preferably at least about 75%, is dissolvoed; after about 30 minutes at least about 80%, more preferably at least about 85%, is dissolved; and after about 40 minutes at least about 90%, preferably at least about 95%, and more preferably about 98% to about 100%, is dissolved, when determined under conditions at least as stringent as 1000 mL of 0.05 M aqueous SLS solution, padddle at 75 rpm, at 37°C.

What Is Claimed Is:

1. A granulate for pharmaceutical composition, comprising an active pharmaceutical ingredient having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, wherein the active pharmaceutical ingredient has a solubility in water of less than about 20 mg/ml, with the proviso that when the active pharmaceutical ingredient is fenofibrate the at least one pharmaceutically acceptable sugar is not lactose.

2. The granulate of claim 1, further comprising at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar.

3. The granulate of claim 2, wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of diluents, binders, disintegrants, wetting agents, lubricants, glidants, coloring agents and flavoring agents.

4. The granulate of claim 3, wherein the diluents are microcrystalline cellulose, lactose and starch, the binders are carboxymethylcellulose sodium, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone, sodium alginate and starch, and the disintegrants are croscarmellose sodium, crospovidone, microcrystalline cellulose, pregelatinized starch and sodium starch glycolate.

5. The granulate of claim 3, wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of polymers or copolymers of vinyl pyrrolidone, croscarmellose sodium, microcrystalline cellulose and sodium lauryl sulfate.

6. The granulate of claim 5, wherein the at least one pharmaceutically acceptable excipient other than the polymers or copolymers of vinyl pyrrolidone are selected from povidone and crospovidone.

7. The granulate of claim 6, wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar comprises povidone, microcrystalline cellulose and sodium lauryl sulfate.

8. The granulate of claim 7, wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar comprises povidone, microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium and colloidal silicon dioxide.

9. The granulate of claim 1, wherein the at least one pharmaceutically acceptable sugar is selected from mannitol, sorbitol, glucose, fructose, galactose, sucrose, maltose, isomaltose, cellobiose, melibiose, gentiobiose and lactose.

10. The granulate of claim 1, wherein the at least one pharmaceutically acceptable sugar comprises a pharmaceutically acceptable disaccharide.

11. The granulate of claim 10, wherein the at least one pharmaceutically acceptable sugar comprises a pyranosyl pyranose.

12. The granulate of claim 11, wherein the pyranosyl pyranose is selected from maltose, isomaltose, cellobiose, lactose, melibiose and gentiobiose.

13. The granulate of claim 12, wherein the at least one pharmaceutically acceptable sugar is lactose.

14. The granulate of claim 1, wherein the active pharmaceutical ingredient is selected from fenofibrate, bicalutamide, atorvastatin, fluvastatin, simvastatin, candesartan, ezetimibe, oxcarbazepine, meloxicam, celecoxib, rofecoxib, valdecoxib, raloxifene, aripiprazole and glyburide.

15. The granulate of claim 14, wherein the active pharmaceutical ingredient is bicalutamide.

16. The granulate of claim 15, wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar comprises povidone, microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium and colloidal silicon dioxide.

17. The granulate of claim 16, wherein the at least one pharmaceutically acceptable sugar is lactose or lactose monohydrate, and wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar comprises povidone, microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate.

18. A pharmaceutical dosage form, comprising the granulate of claim 1.

19. The pharmaceutical dosage form of claim 18, wherein the at least one pharmaceutically acceptable sugar is lactose.

20. The pharmaceutical dosage form of claim 19 wherein the granulate further comprises at least one pharmaceutically acceptable excipient selected from a filler, glidant, binder, disintegrant, surfactant and lubricant.

21. The pharmaceutical dosage form of claim 20, wherein the filler is microcrystalline cellulose, the glidant is silicon dioxide, the binder is povidone, the disintegrant is croscarmellose sodium, the surfactant is sodium lauryl sulfate and the lubricant is magnesium stearate.

22. The pharmaceutical dosage form of claim 18, wherein the active pharmaceutical ingredient is bicalutamide, wherein at least 50% of the bicalutamide dissolves in about 15 minutes when tested under conditions at least as stringent as 1000 ml of a 1% aqueous solution of sodium lauryl sulfate at 37° C using a USP paddle method rotating at 50 rpm when measured by a UV detector at 272 nm.

23. The pharmaceutical dosage form of claim 18, wherein the active pharmaceutical ingredient is bicalutamide, wherein at least 65% of the bicalutamide dissolves in about 30 minutes when tested under conditions at least as stringent as 1000 ml of a 1% aqueous

solution of sodium lauryl sulfate at 37° C using a USP paddle method rotating at 50 rpm when measured by a UV detector at 272 nm.

24. The pharmaceutical dosage form of claim 18, wherein the active pharmaceutical ingredient is bicalutamide, wherein at least 75% of the bicalutamide dissolves in about 45 minutes when tested under conditions at least as stringent as 1000 ml of a 1% aqueous solution of sodium lauryl sulfate at 37° C using a USP paddle method rotating at 50 rpm when measured by a UV detector at 272 nm.

25. The pharmaceutical dosage form of claim 22, wherein about 80% of the bicalutamide dissolves in about 15 minutes when tested under conditions at least as stringent as 1000 ml of a 1% aqueous solution of sodium lauryl sulfate at 37° C using a USP paddle method rotating at 50 rpm when measured by a UV detector at 272 nm.

26. The pharmaceutical dosage form of claim 23, wherein about 95% of the bicalutamide dissolves in about 30 minutes when tested under conditions at least as stringent as 1000 ml of a 1% aqueous solution of sodium lauryl sulfate at 37° C using a USP paddle method rotating at 50 rpm when measured by a UV detector at 272 nm.

27. The pharmaceutical dosage form of claim 25 comprising no sodium starch glycolate.

28. The pharmaceutical dosage form of claim 26 comprising no sodium starch glycolate.

29. The pharmaceutical dosage form of claim 24, wherein the active pharmaceutical ingredient is bicalutamide, wherein about 100% of the bicalutamide dissolves in about 45 minutes when tested under conditions at least as stringent as 1000 ml of a 1% aqueous solution of sodium lauryl sulfate at 37° C using a USP paddle method rotating at 50 rpm when measured by a UV detector at 272 nm, with the proviso that the pharmaceutical dosage form does not comprise sodium starch glycolate.

30. A process for making a pharmaceutical granulate, comprising

(a) combining

an active pharmaceutical ingredient having poor water solubility,

a solution comprising at least one pharmaceutically acceptable sugar and, optionally, at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a mixture, wherein the active pharmaceutical ingredient has a water solubility of less than about 20 mg per ml of water, and wherein the solution comprises the at least one pharmaceutically acceptable sugar and at least one solvent;

(b) drying the mixture; and

(c) comminuting the product of step (b) to obtain the pharmaceutical granulate.

31. The process of claim 30, wherein the at least one solvent is water.

32. The process of claim 30, wherein the active pharmaceutical ingredient and the at least one pharmaceutically acceptable sugar are combined with the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar in step (a), and the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents.

33. The process of claim 32, wherein the diluents are microcrystalline cellulose, lactose and starch, the binders are carboxymethylcellulose sodium, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone, sodium alginate and starch, and the disintegrants are croscarmellose sodium, crospovidone, microcrystalline cellulose, pregelatinized starch and sodium starch glycolate.

34. The process of claim 33, wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of polymers or copolymers of vinyl pyrrolidone, croscarmellose sodium, microcrystalline cellulose and sodium lauryl sulfate.

35. The process of claim 34, wherein the polymers or copolymers of vinyl pyrrolidone are selected from povidone and crospovidone.

36. The process of claim 35, wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar comprises povidone, microcrystalline cellulose and sodium lauryl sulfate.

37. The process of claim 36, wherein the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar comprises povidone, microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium and colloidal silicon dioxide.

38. The process of claim 30, wherein the at least one pharmaceutically acceptable sugar is selected from mannitol, sorbitol, glucose, fructose, galactose, sucrose, maltose, isomaltose, cellobiose, melibiose, gentiobiose and lactose.

39. The process of claim 30, wherein the at least one pharmaceutically acceptable sugar comprises a pharmaceutically acceptable disaccharide.

40. The process of claim 39, wherein the at least one pharmaceutically acceptable sugar comprises a pyranosyl pyranose.

41. The process of claim 40, wherein the pyranosyl pyranose is selected from maltose, isomaltose, cellobiose, lactose, melibiose and gentiobiose.

42. The process of claim 41, wherein the at least one solvent is water, and the at least one pharmaceutically acceptable sugar is lactose.

43. The process of claim 30, wherein the at least one solvent is water, and the aqueous solution of the at least one pharmaceutically acceptable sugar mixed with the active pharmaceutical ingredient in step (a) contains between about 0.05:1 to about 1:0.05 weight of the at least one pharmaceutically acceptable sugar:weight of water.

44. The process of claim 43, wherein the aqueous solution of the at least one pharmaceutically acceptable sugar mixed with the active pharmaceutical ingredient in step (a) contains between about 0.1:1 to about 1:0.1 weight of the at least one pharmaceutically acceptable sugar:weight of water.

45. The process of claim 44, wherein the aqueous solution of the at least one pharmaceutically acceptable sugar mixed with the active pharmaceutical ingredient in step (a) contains between about 0.5:1 to about 1:0.5 weight of the at least one pharmaceutically acceptable sugar:weight of water.

46. The process of claim 42, wherein the aqueous solution of the at least one pharmaceutically acceptable sugar mixed with the active pharmaceutical ingredient in step (a) contains about 1:1 weight of the at least one pharmaceutically acceptable sugar:weight of water.

47. The process of claim 30, wherein the following substances are combined in step (a):

from about 0.3 to about 75 wt.-% of the active pharmaceutical ingredient,
from about 5 to about 45 wt.-% of a diluent,
from about 5 to about 15 wt.-% of a disintegrant,
from about 0.5 to about 8 wt.-% of a binder,
from about 1 to about 10 wt.-% of of a wetting agent, and
from about 1 to about 50 wt-% of the solution (sugar +solvent) of the at least one pharmaceutically acceptable sugar (about 1:1, sugar weight:solvent weight).

48. The process of claim 47, wherein the at least one pharmaceutically acceptable sugar is lactose, and the solvent is water.

49. The process of claim 47, wherein the combining of step (a) is performed in a high shear mixer.

50. The process of claim 30, further comprising blending the product of step (b) with colloidal silicon dioxide prior to step (c).

51. The process of claim 30, wherein the active pharmaceutical ingredient is selected from fenofibrate, bicalutamide, atorvastatin, fluvastatin, simvastatin, candesartan, ezetimibe, oxcarbazepine, meloxicam, celecoxib, rofecoxib, valdecoxib, raloxifene, aripiprazole and glyburide.

52. The process of claim 51, wherein the active pharmaceutical ingredient is bicalutamide.

53. The process of claim 52, wherein the pharmaceutically acceptable sugar comprises lactose monohydrate, and the at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar comprises microcrystalline cellulose, colloidal silicon dioxide, povidone, croscarmellose sodium, sodium lauryl sulfate and magnesium stearate.

54. The process of claim 52, wherein bicalutamide, microcrystalline cellulose, povidone, croscarmellose sodium, sodium lauryl sulfate and an aqueous solution of lactose monohydrate are combined in step (a) to form the mixture.

55. The process of claim 54, further comprising blending the product of step (b) with colloidal silicon dioxide to obtain a blend prior to step (c).

56. The process of claim 55, wherein step (c) is performed by milling the blend from step (b).

57. The process of claim 56, further comprising mixing the milled blend with microcrystalline cellulose and magnesium stearate to obtain a mixed granulate and compressing the mixed granulate to form a tablet core.

58. The process of claim 47, wherein 10 to 60 wt.-% of the active pharmaceutical ingredient is used in step (a).

59. A pharmaceutical granulate produced by the process of claim 30.

60. A pharmaceutical granulate produced by the process of claim 42.

61. A pharmaceutical granulate produced by the process of claim 46.

62. A pharmaceutical granulate produced by the process of claim 47.

63. A process of making a pharmaceutical tablet, comprising compressing the granulate for pharmaceutical composition of claim 1 to form a tablet.

64. A process of making a pharmaceutical capsule, comprising filing a capsule shell with the granulate for pharmaceutical composition of claim 1 to obtain the capsule, with optional inclusion of one or more pharmaceutically acceptable excipients.

65. A pharmaceutical tablet produced by the process of claim 63.

66. A pharmaceutical capsule produced by the process of claim 64.

67. The granulate of claim 1, wherein the weight ratio of the at least one pharmaceutically acceptable sugar and the active pharmaceutical ingredient having poor water solubility in the granulate is about 0.1:1 to about 1000:1.

68. The granulate of claim 67, wherein the weight ratio of the at least one pharmaceutically acceptable sugar and the active pharmaceutical ingredient having poor water solubility in the granulate is about 0.1:1 to about 100:1.

69. The granulate of claim 68, wherein the weight ratio of the at least one pharmaceutically acceptable sugar and the active pharmaceutical ingredient having poor water solubility in the granulate is about 0.1:1 to about 10:1.

70. The granulate of claim 69, wherein the active pharmaceutical ingredient having poor water solubility is bicalutamide.

71. The process of claim 30, wherein the at least one pharmaceutically acceptable sugar and the active pharmaceutical ingredient having poor water solubility are combined in step (a) in a weight ratio of about 0.1:1 to about 1000:1.

72. The process of claim 71, wherein the at least one pharmaceutically acceptable sugar and the active pharmaceutical ingredient having poor water solubility are combined in step (a) in a weight ratio of about 0.1:1 to about 100:1.

73. The process of claim 72, wherein the at least one pharmaceutically acceptable sugar and the active pharmaceutical ingredient having poor water solubility are combined in step (a) in a weight ratio of about 0.1:1 to about 10:1.

74. The process of claim 30, wherein the active pharmaceutical ingredient having poor water solubility is bicalutamide.

75. The process of claim 30, wherein the active pharmaceutical ingredient having poor water solubility is fenofibrate.

76. The process of claim 30, wherein the solution used in step (a) has a weight ratio of the at least one pharmaceutically acceptable sugar and a solvent of about 0.05:1 to about 1:0.05.

77. The process of claim 30, wherein the active pharmaceutical ingredient is fenofibrate, wherein at least about 50% of the fenofibrate dissolves in about 10 minutes when the pharmaceutical granulate is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

78. The process of claim 77, wherein at least about 60% of the fenofibrate dissolves in about 10 minutes when the pharmaceutical granulate is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

79. The process of claim 78, wherein at least about 70% of the fenofibrate dissolves in about 20 minutes when the pharmaceutical granulate is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

80. The process of claim 79, wherein at least about 80% of the fenofibrate dissolves in about 30 minutes when the pharmaceutical granulate is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

81. The process of claim 80, wherein at least about 90% of the fenofibrate dissolves in about 40 minutes when the pharmaceutical granulate is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

82. The process of claim 81, wherein at least about 95% of the fenofibrate dissolves in about 40 minutes when the pharmaceutical granulate is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm..

83. The process of claim 51, wherein fenofibrate, polyvinyl pyrrolidone, sodium starch glycolate, croscarmellose sodium, crospovidone, microcrystalline cellulose, sodium lauryl sulfate and an aqueous solution of lactose are combined in step (a) to form the mixture.

84. The process of claim 83, further comprising blending Aerosil with the product of step (b)

85. The process of claim 84, further comprising blending sodium stearyl fumarate with the product of the process of claim 83.

86. The granulate of claim 14, wherein the active pharmaceutical ingredient is fenofibrate.

87. A granulate for pharmaceutical composition, comprising an active pharmaceutical ingredient having a poor water solubility comprised of fenofibrate intimately associated with at least one pharmaceutically acceptable sugar, and the particle size distribution of the granulate is such that at least about 75 percent of the granulate pass through an 80 mesh screen.

88. The granulate of claim 87 where at least about 66 percent of the granulate passes through a 100 mesh screen.

89. The process of claim 30, wherein the at least one pharmaceutically acceptable sugar comprises at least lactose, and wherein the solution comprising the at least one pharmaceutically acceptable sugar is between at least about 15 percent and about 60 percent of the weight of the mixture formed in the combining step (a).

90. The process of claim 89, wherein the solution is between at least about 35 percent and about 50 percent of the weight of the mixture formed in the combining step (a).

91. The process of claim 90, wherein the solution is about 40 percent of the weight of the mixture formed in the combining step (a).

92. The process of claim 30, wherein the at least one pharmaceutically acceptable sugar comprises at least lactose, and wherein the solution comprising the at least one pharmaceutically acceptable sugar is prepared by heating a mixture of lactose and water at a temperature of about 70 °C.

93. The pharmaceutical dosage form of claim 18, wherein at least about 50% of the active pharmaceutical ingredient dissolves in about 10 minutes when the pharmaceutical dosage form is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

94. The pharmaceutical dosage form of claim 93, wherein at least about 70% of the active pharmaceutical ingredient dissolves in about 20 minutes when the pharmaceutical dosage form is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

95. The pharmaceutical dosage form of claim 94, wherein at least about 80% of the active pharmaceutical ingredient dissolves in about 30 minutes when the pharmaceutical dosage form is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

96. The pharmaceutical dosage form of claim 95, wherein at least about 90% of the active pharmaceutical ingredient dissolves in about 40 minutes when the pharmaceutical dosage form is tested under conditions at least as stringent as 1000 ml of a 0.05 M aqueous sodium lauryl sulfate solution at 37°C using a USP paddle method rotating at 75 rpm.

97. A pharmaceutical dosage form comprising the granulate of claim 87.

98. A pharmaceutical dosage form comprising the granulate of claim 88.


Test condition: 1000cc 0.05M SLS , 75rpm paddle, 37°C
120.0
100.0
80.0
60.0
40.0
20.0
0.0
%Dissolved
0
10
20
30
40
50
Time (min)
K-29740
Tricor 160mg

Figure 1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/025326

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/00 A61K9/16 A61K31/542 A61K31/5415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ANONYMOUS: "FORMULATIONS COMPRISING LIPID-REGULATING AGENTS" IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 11 July 2002 (2002-07-11), XP013003768 ISSN: 1533-0001 the whole document	1-98
X	US 6 074 670 A (STAMM ET AL) 13 June 2000 (2000-06-13) claims 1-38; examples 1-4 -/--	1-14, 18-21, 30-42, 51, 59-61, 63-69, 71-76, 86-88, 97,98

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 October 2005	28/10/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Kardas-Llorens, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/025326

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 102 50 081 A1 (BOEHRINGER INGELHEIM VETMEDICA GMBH) 13 May 2004 (2004-05-13) paragraphs '0014! - '0017!; claims 1-16; examples 1-4	1-14, 18-21, 30-51, 59-62, 67-69, 71-73,76
X	EP 0 945 134 A (BOEHRINGER INGELHEIM PHARMA KG) 29 September 1999 (1999-09-29) paragraph '0034! - paragraph '0035!; claims 1-15; examples 6,7	1-14, 18-21, 30-42, 51, 59-61, 63-69, 71-76, 86-88, 97,98
X	US 2004/058935 A1 (BANDO TAKUJI ET AL) 25 March 2004 (2004-03-25) paragraphs '0163! - '0171!, '0251! - '0256!, '0465! - '0477!; claims 1-157; examples 4,5	1-14, 18-21, 30-42, 51, 59-61, 63-69, 71-76, 86-88, 97,98
X	WO 02/15884 A (PHARMACIA CORPORATION; KARARLI, TUGRUL, T; KONTNY, MARK, J; LE, TRANG,) 28 February 2002 (2002-02-28) page 31, paragraph 1; claims 1-39	18, 63-66, 97,98

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/025326

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6074670 A	13-06-2000	AT 291911 T	15-04-2005
		AT 233556 T	15-03-2003
		AU 731964 B2	05-04-2001
		AU 5336798 A	07-08-1998
		BR 9806738 A	29-02-2000
		CA 2219475 A1	17-07-1998
		CN 1496738 A	19-05-2004
		CY 2396 A	10-09-2004
		CZ 9902535 A3	17-11-1999
		DE 69811855 D1	10-04-2003
		DE 69811855 T2	18-12-2003
		DE 69829591 D1	04-05-2005
		DK 952829 T3	23-06-2003
		EE 9900296 A	15-02-2000
		EP 0952829 A1	03-11-1999
		ES 2195308 T3	01-12-2003
		FR 2758459 A1	24-07-1998
		HK 1023071 A1	15-08-2003
		HU 0000808 A2	28-12-2000
		WO 9831361 A1	23-07-1998
		ID 22528 A	28-10-1999
		IN 187906 A1	20-07-2002
		JP 2001511156 T	07-08-2001
		JP 2005206614 A	04-08-2005
		MA 26466 A1	20-12-2004
		NO 993519 A	16-09-1999
		NZ 336462 A	29-09-2000
		PL 334748 A1	13-03-2000
		PT 1273293 T	30-06-2005
		PT 952829 T	31-07-2003
		RU 2196580 C2	20-01-2003
		RU 2236850 C2	27-09-2004
		RU 2238089 C2	20-10-2004
		SK 96299 A3	14-08-2000
		TR 9901660 T2	21-09-1999
		UA 61096 C2	15-08-2000
		ZA 9800324 A	12-08-1998
DE 10250081 A1	13-05-2004	AU 2003276170 A1	13-05-2004
		BR 0315639 A	30-08-2005
		CA 2503396 A1	06-05-2004
		WO 2004037264 A1	06-05-2004
		EP 1558262 A1	03-08-2005
EP 0945134 A	29-09-1999	AT 254920 T	15-12-2003
		AU 762322 B2	26-06-2003
		AU 3417199 A	18-10-1999
		BR 9909192 A	05-12-2000
		CA 2326517 A1	07-10-1999
		CN 1295478 A	16-05-2001
		DE 59907871 D1	08-01-2004
		DK 1083902 T3	29-03-2004
		WO 9949867 A1	07-10-1999
		ES 2212547 T3	16-07-2004
		HK 1034183 A1	21-01-2005
		HU 0101246 A2	29-05-2002
		JP 3639532 B2	20-04-2005
		JP 2002509886 T	02-04-2002

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/025326

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0945134 A		NO 20004823 A	22-11-2000
		NZ 507382 A	29-08-2003
		PL 342988 A1	16-07-2001
		PT 1083902 T	30-04-2004
		TR 200002786 T2	22-01-2001
		ZA 200004178 A	20-02-2002
US 2004058935 A1	25-03-2004	AU 2002334413 B2	04-11-2004
		BR 0205391 A	29-07-2003
		CN 1463191 A	24-12-2003
		EP 1330249 A1	30-07-2003
		WO 03026659 A1	03-04-2003
		MX PA03000440 A	06-10-2003
		PL 360900 A1	20-09-2004
WO 0215884 A	28-02-2002	AU 8501101 A	04-03-2002
		CA 2419592 A1	28-02-2002
		EP 1309315 A2	14-05-2003
		JP 2004506680 T	04-03-2004
		MX PA03001407 A	06-06-2003
		NZ 524124 A	24-09-2004